about
Adherence with capecitabine: A population-based analysis based on prescription refill data.Defining the clinical improvement in cancer drug therapy: implications for priority setting in healthcare.Development of a systematic approach to pharmaceutical industry's patient assistance programs on accessing unfunded cancer drugs.Clinical effectiveness of bevacizumab in patients with recurrent brain tumours: A population-based evaluation.Pharmacy research by "nonresearch pharmacists".Seeking clarification of osteoporosis guidelines.Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin.Interaction between mercaptopurine and milk.Pharmacist's role in meeting the psychosocial needs of cancer patients using complementary therapy.Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.Loperamide and cardiac events: Is high-dose use still safe for chemotherapy-induced diarrhea?Comment: evaluation of the modified diet in renal disease equation for calculation of carboplatin dose.A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision.Challenges of dispensing costly tablets with short shelf-life.Clinical efficacy of generic imatinibEvaluation of the role of pharmacy technicians in reviewing the eligibility for Oncotype DX genomic test and the impact of the test on treatment plans in breast cancer patientsEvaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignanciesAdvising cancer patients on natural health products--a structured approachCommunicating with patients about chemotherapy costsImpact on patient satisfaction with a structured counselling approach on natural health productsEvidence-based practice in times of drug shortageTrastuzumab therapy in breast cancer: To reload or not to reload?Rationalizing the use of auxiliary label for oral oncology drugsEfficacy of bevacizumab and temozolomide therapy in locally advanced, recurrent, and metastatic malignant solitary fibrous tumour: A population-based analysisSafe handling of monoclonal antibodies: Too large to be hazardous?International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive careEfficacy of nivolumab four-weekly dosing schedule based on body weightConcomitant use of capecitabine and proton pump inhibitors - Is it safe?Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinomaClinical considerations of hyaluronidase as an adjunct to subcutaneous rituximab injectionPhytoestrogens and menopause. Pharmacological attributes of plant based drugs should be discussed widelyStorm over screening for prostate specific antigen. Number needed to test needs to be known
P50
Q31140272-FF3FB26E-84ED-4A8E-8A59-8B59647639E3Q36597891-8869EC97-FF4D-4A4F-80C1-E99A704396DAQ39005950-C2664E3D-E802-4577-831F-540425F7CABBQ39024958-1DA639E7-AA46-4C7A-938B-C963F2ED064BQ42858510-822847A6-9B71-4238-B5FF-AA0C71C01712Q43294076-1AF0C6F3-DFA6-4EFE-8E96-6BDF9F0CBB62Q45939582-626D37CC-D7F5-4D47-B546-60972A033610Q46876648-3FEAD561-89EE-4292-BC80-DAF4DF15BD5EQ47629310-7E4CE98D-FC57-4005-B843-3728F92D776EQ49338688-ABF9E45F-9F61-46C8-AA51-A98E797AC65AQ50527887-1E8B525C-2DB0-40BC-9F96-F6B99873079CQ51782088-1E40ADD5-3A95-4114-A142-333766275E87Q53141055-6751D018-7FE1-44AC-9469-0347910F6028Q53819103-6F942F2E-4053-41B6-AC67-1A592A3A11CCQ57108016-AAC6E260-7B1B-473A-94EF-E341423E756EQ57804040-28B640EE-5B02-4FF8-8EB9-3357EAE3BC18Q80019801-3415A632-BE10-43CB-B57B-FE26ACAA9CC3Q80337612-0A6D98CE-12B8-499A-9CBC-203B3057CE7FQ80358669-5F9E9456-A7D0-4575-B223-35F2965F5422Q80862458-E4B2F46C-6D0E-4395-8AF5-10B295EDC198Q85313642-CC9586D8-561A-45C8-8B89-5902905D89A4Q86491206-576BB37F-01C9-41A9-910B-4230D1171AE7Q89252332-37948DAF-829D-4F3B-8253-B8C110AC1EEBQ89264564-35B253B6-09F0-47A9-BCAD-30E0DE3AB8C5Q89748002-2A8DBECB-B7AB-419C-85C6-8EC7C029EE8BQ91735971-321117D3-642D-409B-AD3E-9245274D3ABDQ91939342-D9D088F8-3372-44BC-A8C0-811342FE0DDDQ91969240-8195F306-8379-40F1-9D19-98BD69F12400Q92607069-FFDB3FFE-97C8-4F6C-8849-E1528126EB1FQ93034783-11E8DA22-6C6E-44D1-AE8D-3A58D2FA3F90Q95801428-F503AB35-156F-466B-AC6E-18BE681A145CQ95811353-094DA17C-915B-43BF-8B80-E28097046223
P50
description
investigador
@es
researcher
@en
name
Mário L de Lemos
@en
type
label
Mário L de Lemos
@en
prefLabel
Mário L de Lemos
@en
P31
P496
0000-0002-8284-4893